ACTIN Report (research use only)

PATIENT
EXAMPLE-CRC-01

REPORT DATE
17-Sep-2025

Gender: Female | Birth year: 1946 | WHO: 0

Tumor: Colorectum (cecum) carcinoma | Lesions: Lung, Peritoneal | Stage: IV

Clinical summary

Relevant systemic treatment history	**None**	
Relevant other oncological history	**11/2021**	**Hemicolectomy right (Cecum)**
Previous primary tumor	**Skin squamous cell carcinoma (diagnosed 6/2016, last treatment 8/2016, considered non-active)**	
Relevant non-oncological history	**1/2019**	**Cerebrovascular accident**

Standard-of-care options considered potentially eligible

Treatment	Literature efficacy evidence	Real-world efficacy evidence	Warnings
FOLFIRI	PHASE-3-CRC		
	PFS: 10.0 months (95% CI: 10.0-12.0)	**PFS:** 13.3 months, IQR: 12.6	
	OS: 25.0 months (95% CI: 25.0-30.0)	**OS:** 22.2 months, IQR: 24.8	

Trials in NL that are open and potentially eligible (1 cohort from 1 trial)

Trial	Cohort	Molecular	Sites	Warnings
KRAS-G12D-TRIAL	*KRAS G12D*	*KRAS G12D*	*UMC Utrecht*	

Trials matched solely on molecular event and tumor type (no clinical data used) are shown in italicized, smaller font.

All results and data described in this report are for Research Use Only and have NOT been generated using a clinically validated and controlled procedure nor is it a validated medical device. The results should NOT be used for diagnostic or treatment purposes. No rights can be derived from the content of this report.
Gene and variant annotations and related content are powered by Genomenon Cancer Knowledgebase (CKB).

Molecular Details

NGS & MSI Panel (15-Jan-2023)

Biopsy location	**Lung**
Tumor mutational burden	**TMB 8 mut/Mb**
Microsatellite (in)stability	**Stable**
Driver mutations	**KRAS G12D**

IHC results

Ki67	**Positive, score 90%**
PD-L1	**Score < 50%**

All results and data described in this report are for Research Use Only and have NOT been generated using a clinically validated and controlled procedure nor is it a validated medical device. The results should NOT be used for diagnostic or treatment purposes. No rights can be derived from the content of this report.

Gene and variant annotations and related content are powered by Genomenon Cancer Knowledgebase (CKB).

Efficacy evidence

Standard of care options considered potentially eligible

The following standard of care treatment(s) could be an option for this patient. For further details per study see 'SOC literature details' section in extended report.

Treatment	Literature efficacy evidence
FOLFIRI	PHASE-3-CRC **Patient characteristics:** WHO/ECOG: 0: 100, 1: 80, 2: 20, 3: 0, 4: 0 Primary tumor location: Left: 145, Both or unknown: 10, Right: 45 Mutations: KRAS exon 2 wild-type 200/200 Metastatic sites: Liver only: 58 (32.0%), Lung only: 10 (6.0%) Previous systemic therapy: 35/200 Prior therapies: Adjuvant chemotherapy **Median PFS:** 10.0 months (95% CI: 10.0-12.0) **Median OS:** 25.0 months (95% CI: 25.0-30.0)

Treatment decisions (percentage of population assigned to systemic treatment) in NCR real-world data set

	All (n=9207)	Age 73-83y (n=2727)	WHO 1 (n=2828)	RAS positive (n=2760)	Liver only lesions (n=2715)
FOLFIRI	38.5%	23.8%	37.9%	44.6%	39.5%

Median overall survival (OS) in months in NCR real-world data set

	All (n=9207)	Age 73-83y (n=2727)	WHO 1 (n=2828)	RAS positive (n=2760)	Liver only lesions (n=2715)
FOLFIRI	**16.1**, IQR: 18.2 (n=3543)	**15.4**, IQR: 18.2 (n=649)	**14.8**, IQR: 16.3 (n=1071)	**15.8**, IQR: 14.2 (n=1230)	**16.5**, IQR: 17.4 (n=1073)

All results and data described in this report are for Research Use Only and have NOT been generated using a clinically validated and controlled procedure nor is it a validated medical device. The results should NOT be used for diagnostic or treatment purposes. No rights can be derived from the content of this report.
Gene and variant annotations and related content are powered by Genomenon Cancer Knowledgebase (CKB).

Median progression-free survival (PFS) in months in NCR real-world data set

	All (n=5018)	Age 73-83y (n=1330)	WHO 1 (n=1623)	RAS positive (n=1822)	Liver only lesions (n=1534)
FOLFIRI	**8.2**, IQR: 5.5 (n=2106)	**8**, IQR: 6.1 (n=340)	**7.9**, IQR: 5 (n=661)	**8**, IQR: 4.7 (n=836)	**8.3**, IQR: 5.3 (n=652)

Explanation:

These tables only show treatments that are considered standard of care (SOC) in colorectal cancer in the Netherlands.

The ‘All’ column shows results in NCR patients who were previously untreated, diagnosed with colorectal cancer with distant metastases and treated systemically without surgery, for whom the treatment could be categorized in SOC treatments.

The ‘Age’, ‘WHO’, ‘RAS’ and ‘Lesions’ columns show results based on patients from the ‘All’ population, filtered for equal WHO, similar age, equal RAS status or equal lesion localization, respectively.

‘PFS’ is calculated as the duration from the date on which the first compound of the treatment was administered, until first progression.

‘OS’ is calculated as the duration from the date on which the first compound of the treatment was administered, until death from any cause.

When patient number is too low (n <= 20) to predict PFS or OS, "NA" is shown.

All results and data described in this report are for Research Use Only and have NOT been generated using a clinically validated and controlled procedure nor is it a validated medical device. The results should NOT be used for diagnostic or treatment purposes. No rights can be derived from the content of this report.

Gene and variant annotations and related content are powered by Genomenon Cancer Knowledgebase (CKB).

PATIENT
EXAMPLE-CRC-01

REPORT DATE
17-Sep-2025



All results and data described in this report are for Research Use Only and have NOT been generated using a clinically validated and controlled procedure nor is it a validated medical device. The results should NOT be used for diagnostic or treatment purposes. No rights can be derived from the content of this report.
Gene and variant annotations and related content are powered by Genomenon Cancer Knowledgebase (CKB).



All results and data described in this report are for Research Use Only and have NOT been generated using a clinically validated and controlled procedure nor is it a validated medical device. The results should NOT be used for diagnostic or treatment purposes. No rights can be derived from the content of this report.
Gene and variant annotations and related content are powered by Genomenon Cancer Knowledgebase (CKB).



All results and data described in this report are for Research Use Only and have NOT been generated using a clinically validated and controlled procedure nor is it a validated medical device. The results should NOT be used for diagnostic or treatment purposes. No rights can be derived from the content of this report.
Gene and variant annotations and related content are powered by Genomenon Cancer Knowledgebase (CKB).



Resistance evidence

Treatment	Mutation	Evidence source	Evidence level	Found in molecular analysis
FOLFIRI	GENE S11C	[1]	D	Yes

All results and data described in this report are for Research Use Only and have NOT been generated using a clinically validated and controlled procedure nor is it a validated medical device. The results should NOT be used for diagnostic or treatment purposes. No rights can be derived from the content of this report.
Gene and variant annotations and related content are powered by Genomenon Cancer Knowledgebase (CKB).

Clinical Details

Clinical summary

Relevant systemic treatment history	**None**	
Relevant other oncological history	**11/2021**	**Hemicolectomy right (Cecum)**
Previous primary tumor	**Skin squamous cell carcinoma (diagnosed 6/2016, last treatment 8/2016, considered non-active)**	
Relevant non-oncological history	**1/2019**	**Cerebrovascular accident**

Patient current details (05-Mar-2023)

Unresolved toxicities grade => 2	**None**
Known allergies	**Morphine**
Recent surgeries	**12-Nov-2021 Hemicolectomy right**

Tumor details (05-Mar-2023)

Measurable disease	**Yes**
Known lesions	**Lung, Peritoneal**
Unknown lesions	**Lymph node**
No lesions present	**CNS, Brain, Liver, Bone**

Active medication details

Medication	Administration route	Start date	Stop date	Dosage	Frequency
None					

Blood transfusions

Product	Date
ERTHROCYTES_FILTERED	10-Jan-2023

All results and data described in this report are for Research Use Only and have NOT been generated using a clinically validated and controlled procedure nor is it a validated medical device. The results should NOT be used for diagnostic or treatment purposes. No rights can be derived from the content of this report.
Gene and variant annotations and related content are powered by Genomenon Cancer Knowledgebase (CKB).

Trial Matching Details

Trials and cohorts that are potentially eligible, but are closed (2)

Trial	Cohort	Molecular	Sites	Warnings
METC 01 IEMOEN	*Applies to all cohorts below*	None		Has not exhausted SOC
	Dose escalation - monotherapy			
	Dose expansion - monotherapy			

Trials and cohorts that are considered ineligible (2)

Trial	Cohort	Molecular	Ineligibility reasons
METC 02 KAYRAS	*Applies to all cohorts below*	KRAS G12D	PD-L1 expression below minimum of 50.0
	Dose expansion - monotherapy - Colorectum		
	Dose expansion - monotherapy - NSCLC		No lung non-small cell carcinoma

Trials and cohorts that are not evaluable or ignored (0)

Trial	Cohort	Molecular	Sites	Configuration
None				

All results and data described in this report are for Research Use Only and have NOT been generated using a clinically validated and controlled procedure nor is it a validated medical device. The results should NOT be used for diagnostic or treatment purposes. No rights can be derived from the content of this report.

Gene and variant annotations and related content are powered by Genomenon Cancer Knowledgebase (CKB).